Volume : 11, Issue : 11, November – 2024

Title:

RISKS AND OPPORTUNITIES IN DEVELOPMENT OF NEW DRUG IN UK, US AND INDIA

Authors :

D SAI PRIYA*, M BEENA DEVI, M. V. NAGABHUSHANAM, ADILAKSHMI CH,G RAMAKRISHNA

Abstract :

This review paper explores the risks and opportunities associated with the development of new drugs in three major pharmaceutical markets: the United Kingdom (UK), the United States (US), and India. Each of these regions has distinct regulatory, economic, and market dynamics, influencing the drug development process and the overall pharmaceutical landscape. Understanding these factors is critical for pharmaceutical companies aiming to develop and commercialize innovative drugs on a global scale.
Keywords: Risks and Opportunities, Regulatory frameworks, Approval Process, Generic Drugs, United Kingdom (UK), the United States (US), and India

Cite This Article:

Please cite this article in press D Sai Priya et al Risks And Opportunities In Development Of New Drug In Uk, Us And India.,Indo Am. J. P. Sci, 2024; 11 (11).

Number of Downloads : 10

References:

1. Munro D. SAS and GSK Pull Big Pharma into Big Data Collaboration.
2. Rajashekar S, Abimanyu S. Risk and Opportunities in Development of New Drug. Research Journal of Pharmacy and Technology. 2020;13(6):3041-4.
3. SENTHIL T, SELVARAJ V, JAWAHAR N, VENKATACHALAM S. An Overview of Indian Veterinary Medicine Regulation. International Journal of Pharmaceutical Research (09752366). 2020 Jul 2.
4. Wang Z, Yang B. General Process for Rational Design and Discovery of MTDs. InPolypharmacology: Principles and Methodologies 2022 Aug 2 (pp. 661-676). Cham: Springer International Publishing.
5. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clinical Pharmacology & Therapeutics. 2010 Mar;87(3):272-7.
6. Katiyar C, Gupta A, Kanjilal S, Katiyar S. Drug discovery from plant sources: An integrated approach. Ayu. 2012 Jan;33(1):10.
7. Drews J. Drug discovery: a historical perspective. science. 2000 Mar 17;287(5460):1960-4.
8. Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2017 Nov 1;3(4):651-7.
9. An overview of new drug discovery and development. (n.d.). PharmaTutor. Retrieved January 2, 2022, from https://www.pharmatutor.org/articles/an-overview-of-new-drug-discovery-and-development
10. Berdigaliyev N, Aljofan M. An overview of drug discovery and development. Future medicinal chemistry. 2020 Feb;12(10):939-47.
11. Steinmetz KL, Spack EG. The basics of preclinical drug development for neurodegenerative disease indications. BMC neurology. 2009 Jun;9(1):1-3.
12. Brahmaiah Bonthagarala, Regulatory Requirements for Registration of Generic Drugs in “BRICS” Countries, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, Issue 6, Vol. 6 (November-December 2016), 20-39.
13. Brahmaiah Bonthagarala,Current Regulatory Requirements for Registration of Medicines, Compilation and Submission of Dossier in Australian Therapeutic Goods Administration, International Journal of Advanced Scientific and Technical Research, ISSN 2249-9954, Issue 6 volume 6, November-December 2016, 144-157.
14. Brahmaiah Bonthagarala,Comparison of Regulatory Requirements for Generic Drugs Dossier Submission in United States and Canada, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, Issue 6, Vol. 6 (November-December 2016), 1-19.
15. Brahmaiah Bonthagarala, Regulatory Requirements for Marketing of Generic Drugs in USA,International Journal of Pharmaceutical Research and Bio-Science, ISSN: 2277-8713, IJPRBS, 2017; Volume 6(2): 178-195.
16. Brahmaiah Bonthagarala,Guidelines for bioavailability and bioequivalence studies: A Review, The Pharma Innovation Journal 2018; 7(7): 661-666, ISSN (E): 2277- 7695.
17. Brahmaiah Bonthagarala et al, Generic Drug Registration and Regulatory Requirements in European Countries,World Journal of Pharmaceutical Research, 2018, Volume 7, Issue 16, 800-815.
18. Pereira J A, Holbrook A M, Dolovich Goldsmith C,Thabane L, Douketus J D, Crowther M, Bates SM,Ginsberg J S. Are brand name and generic warfarin in terchangeable Multiple N-of-1 randomized crossover trials. Annals of Pharmacotherapy. 2005;39:1188-93.